NASDAQ: SNDXSyndax Pharmaceuticals Inc Stock Ownership - Who owns Syndax Pharmaceuticals?
Insider buying vs selling
Have Syndax Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Martin H. Huber Jr. | Director | 2025-05-19 | 5,000 | $8.99 | $44.95kBuy |
| Keith Katkin | Director | 2025-05-19 | 10,000 | $9.11 | $91.12kBuy |
| Nicholas Aj Botwood | Head of RD CMO | 2025-05-16 | 11,765 | $9.00 | $105.83kBuy |
| Michael A. Metzger | Chief Executive Officer | 2025-03-14 | 6,074 | $7.20 | $43.73kBuy |
| Michael A. Metzger | Chief Executive Officer | 2025-03-04 | 7,814 | $7.20 | $56.26kBuy |
| Michael A. Metzger | Chief Executive Officer | 2025-03-04 | 7,814 | $15.05 | $117.56kSell |
| Keith A. Goldan | Chief Financial Officer | 2025-02-10 | 3,777 | $15.50 | $58.56kSell |
| Neil Gallagher | President Head of RD | 2025-02-10 | 4,618 | $15.50 | $71.60kSell |
| Michael A. Metzger | Chief Executive Officer | 2025-02-10 | 13,288 | $15.50 | $206.02kSell |
SNDX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when SNDX insiders and whales buy or sell their stock.
SNDX Shareholders
What type of owners hold Syndax Pharmaceuticals Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Blackrock Inc | 9.93% | 8,542,251 | $87.56M | Institution |
| Kynam Capital Management LP | 9.90% | 8,520,000 | $87.33M | Institution |
| Vanguard Group Inc | 5.66% | 4,871,065 | $49.93M | Institution |
| Eversept Partners LP | 4.90% | 4,212,270 | $43.18M | Institution |
| Point72 Asset Management LP | 4.66% | 4,008,700 | $41.09M | Institution |
| State Street Corp | 4.62% | 3,971,732 | $40.71M | Institution |
| Goldman Sachs Group Inc | 4.56% | 3,921,541 | $40.20M | Institution |
| Citadel Advisors LLC | 3.39% | 2,914,882 | $29.88M | Institution |
| Bank Of America Corp | 3.34% | 2,870,999 | $29.43M | Institution |
| Morgan Stanley | 2.65% | 2,281,916 | $23.39M | Institution |
SNDX vs Biotech Stocks
Syndax Pharmaceuticals Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.